Long‐term remission in a patient with relapsed Richter's transformation treated with CD19‐directed chimeric antigen‐receptor T‐cells after allogeneic stem cell transplantation

Documenti analoghi

• A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T‐cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen receptor T‐cell therapy
  di: Xing‐yu Cao, et al.
  Pubblicazione: (2024)
• CD19 chimeric antigen receptor T‐cell efficacy and toxicity in adults with Richter's transformation and response to bridging therapy
  di: Angela Hwang, et al.
  Pubblicazione: (2025)
• Post‐transplant‐cyclophosphamide and short‐term Everolimus as graft‐versus‐host‐prophylaxis in patients with relapsed/refractory lymphoma and myeloma—Final results of the phase II OCTET‐EVER trial
  di: Tim Richardson, et al.
  Pubblicazione: (2024)
• InsT‐ALLing CD7 chimeric antigen receptors before transplantation
  di: Julio Delgado
  Pubblicazione: (2024)
• CD19 chimeric antigen receptor‐T cell therapy in murine immune thrombocytopenia
  di: Fengjiao Han, et al.
  Pubblicazione: (2025)